These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 14657001)
1. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001 [TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567 [TBL] [Abstract][Full Text] [Related]
3. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856 [TBL] [Abstract][Full Text] [Related]
5. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830 [TBL] [Abstract][Full Text] [Related]
6. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771 [TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro. Magnusson PU; Looman C; Ahgren A; Wu Y; Claesson-Welsh L; Heuchel RL Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2142-9. PubMed ID: 17656670 [TBL] [Abstract][Full Text] [Related]
8. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Pietras K; Hanahan D J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593 [TBL] [Abstract][Full Text] [Related]
9. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489 [TBL] [Abstract][Full Text] [Related]
10. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Inai T; Mancuso M; Hashizume H; Baffert F; Haskell A; Baluk P; Hu-Lowe DD; Shalinsky DR; Thurston G; Yancopoulos GD; McDonald DM Am J Pathol; 2004 Jul; 165(1):35-52. PubMed ID: 15215160 [TBL] [Abstract][Full Text] [Related]
12. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920 [TBL] [Abstract][Full Text] [Related]
13. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Wilkinson-Berka JL; Babic S; De Gooyer T; Stitt AW; Jaworski K; Ong LG; Kelly DJ; Gilbert RE Am J Pathol; 2004 Apr; 164(4):1263-73. PubMed ID: 15039215 [TBL] [Abstract][Full Text] [Related]
16. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Bäckman U; Christofferson R Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357 [TBL] [Abstract][Full Text] [Related]